NCT04409509 - Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

January 12, 2021

Study Completion Date

January 12, 2021

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL

Garadacimab, Factor XIIa Antagonist Monoclonal Antibody

Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously

DRUG

Placebo

CSL312 diluent administered intravenously

Trial Locations (14)

Sisters of Charity Hospital/ St. Joseph's Campus, Buffalo

Inova Alexandria Hospital, Alexandria

Carolina Institute for Clinical Research, Fayetteville

Theia Clinical Research, LLC, St. Petersburg

Nova Clinical Research, LLC, Bradenton

University of Mississippi Medical Center, Jackson

MercyOne North Iowa Medical Center, Mason City

Northeast Iowa Medical Education Foundation, Waterloo

Monument Health Clinical Research, Rapid City

UT Health Science Center, McGovern Medical School, Houston

PharmaTex Research, Amarillo

Lahey Hospital and Medical Center, Burlington

Holy Name Hospital, Teaneck

Inspira Health Center Vineland, Vineland